Duke Hematologic Malignancies & Cellular Therapy

Finishing strong with Monday presentations by our @DukeCancer faculty at #ASH25! Featuring @AndreaSitlinger @ChenyuLinMD @tomleblancMD

Come interact with our faculty and trainees on the Sunday evening poster session #ASH25!

Come check out our @DukeCancer faculty presentations at #ASH25 on Saturday, December 6th!

A strong start to #ASH25 with @LindsayReinMD and #HarryErba kicking off the Friday Satellite Symposia!

DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma. duke.is/w/8xat @DukeMedSchool | @DukeHealth | @DukeHMCT

A warm welcome to our newest faculty member, Dr. Alexander Dew! Dr. Dew joins @DukeCancer from Walter Reed, where he had served as director of autologous stem cell transplantation. He sees patients with plasma cell disorders, including #myeloma. dukehealth.org/find-doctors-p…

CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer ashpublications.org/bloodadvances/…

Take a look at this @FrontiersIn mini-review of reduced & weekly dosing of selinexor in #myeloma, with senior author @Cristin53875581 frontiersin.org/journals/oncol…

📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

Congratulations to @DukeCancer faculty Dr. Yubin Kang for his new @CancerResearch CLIP award studying how targeting SK2 can enhance CAR T cell therapy efficacy in multiple myeloma #mmsm cancerresearch.org/wp-content/upl…

Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses. #MDS | @tomleblancMD @DukeCancer hubs.li/Q03wgGSn0

Take a look at this review of advancements in countermeasures against #radiation injuries from the Centers for Medical Countermeasures against Radiation Consortium (CMCRC), with former @DukeHMCT division chief #NelsonChao as senior author. pubmed.ncbi.nlm.nih.gov/40571995/

This @CIBMTR retrospective study showed that solid organ transplant outcomes following stem cell transplantation varied depending on the organ transplanted. Liver transplants had worse outcomes compared to kidney transplants. Featuring @horwi001 as a co-author. pubmed.ncbi.nlm.nih.gov/40545568/

The BELLINI trial showed that Vd-ven had worse overall survival than Vd-placebo in patients with relapsed multiple #myeloma, indicating that #venetoclax should be avoided in the general R/R myeloma population. Featuring @Cristin53875581 as an author. thelancet.com/journals/lanha…

Congratulations to our faculty @tomleblancMD for this important work!

Explore the complexities of chronic #GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies in this article from Targeted Oncology: hubs.li/Q03tll7V0 | @DukeHMCT @dukemedicine @DukeHealth

Preclinical and early phase clinical data suggests a role for dual #FLT3 and MDM2 inhibition using #quizartinib and #milademetan in FLT3-ITD mutated #AML, featuring faculty #HarryErba as a co-author. @CCR_AACR #leusm aacrjournals.org/clincancerres/…

This cross-sectional study in @JCOOP_ASCO showed that cancer survivors were more likely to get alcohol screening, with similar rates of alcohol intervention when needed, highlighting opportunities for improvement. Featuring Vice-Chief @AndreaSitlinger. ascopubs.org/doi/10.1200/OP…

A multicenter study from the U.S. #MultipleMyeloma Immunotherapy Consortium demonstrated the safety and efficacy of #teclistamab in real-world patients, featuring @DukeU @ChenyuLinMD and #DanielSchrum @BloodCancerJnl #MMsm nature.com/articles/s4140…

We are hiring for a Quality Program manager position for the @DukeCancer @DukeHealth Adult and Pediatric Transplant, Cellular Therapy, and Gene Therapy program. Apply here: careers.dukehealth.org/us/en/job/2586…